Removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A
No approval for either
Seek emergency help immediately (call 999) if, after using any unlicensed peptide compound, you experience any of the following life-threatening symptoms: Signs of anaphylaxis: rash, swelling of the face, lips, or throat, difficulty breathing, or sudden collapse Severe chest pain or palpitations Signs of serious infection (sepsis): high fever, confusion, rapid breathing, or mottled skin following an injection Contact NHS 111 for urgent advice (when symptoms are not immediately life-threatening) if you experience: Persistent or severe nausea, vomiting, or abdominal pain Signs of infection at an injection site: increasing redness, warmth, swelling, pus, or fever Dizziness, fainting, or unexplained changes in blood glucose or metabolic function It is also advisable to inform your GP if you are using or considering any research peptides, even if you feel well
For now, any decision to use GHK-Cu injections should be made with full awareness of the current knowledge and limitations